Prognostic efficacy of TPS in breast cancer

Journal of Tumor Marker Oncology

Volumn 15, Issue 3, 2000, Pages 171-176

  Barak, Vivian ^a   Nisman, Benjamin ^a   Hubert, Ayala ^a   Lyass, Olga ^a   Kaduri, Luna ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27744443340     PISSN: 08863849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Van Dalen A. Tumor markers in breast cancer. Ann Chirurgiae et Gynaecologiae 78:54-64,1989.
2. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapse in breast cancer patients. Breast Cancer Res Treat 36:41-48,1995.
3. Eskelinen M, Tikanoya S, Collan Y. Use of tumor markers CA 15-3, MCA and CEA in breast cancer diagnosis. J Tumor Marker Oncol 4:39-44,1989.
4. Bast Jr R, Bates S, Bredt AB, et al. Clinical practice guidelines for the use of tumor markers in breast cancer and colorectal cancer. J Clin Oncol 10: 2843-2877, 1996.
5. Dnistrian AM, Schwartz MK, Greenberg EJ, et al. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 200: 81-93,1991.
6. Bjorklund B. A conceptual approach to tumor antigen in the past and in the future with special reference to TPS. In: Ballesta A.M. et al (eds). Up-dating on tumor markers in tissue and in biological fluids. Minerva Medica Torino, 1993, pp. 651-669.
7. Liu Q, Nap M, and Oehr P. (1992) The immunohistochemical relation between TPS, Ki67 and proliferation. In: Klapdor R (ed): Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. W. Zuckschwerdt Verlag, München, Bern, Wien, New York, pp. 516-524.
8. Bjorklund B, Einarsson R. TPS (Tissue Polypeptide Specific Antigen) in Oncologic Practice: a Review with Reference to 3000 Cases of Breast Cancer. Tumordiagn u Ther 17:6773,1996.
9. Van Dalen A. TPS in breast cancer A comparative study with carcinoem-bryonic antigen and CA 15-3. Tumor Biol 13:10-17,1992.
10. Van Dalen A.: Is IPS able to assist in decision making in breast cancer? In: R. Klapdor (ed.) Tumor Associated Antigens, Oncogenes, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties. Cancer of the Breast State and Trends in Diagnosis and Therapy, 1992 W.Zuckswerdt Verlag Munchen-Bern-Wien-New York.
11. Bonfrer JMG. Working group on tumor marker criteria (WGTMC). Tumor Biol 11:287-288,1990.
12. Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Baider L, Kaplan A, Halperin T, Stephanos S, and Peretz T. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J Tumor Marker Oncology 12(4): 17-26,1997.
13. Barak V, Gimmon Z, Libson Y, Peretz T, Nisman B, Lifshitz I, Durst A, Roisman I. Breast cancer detection by mammography, Ca15-3 and TPS. J Tumor Marker Oncology 10(2):5152,1995.
14. Van Dalen A, Heering KJ (Gouda), Barak V, Peretz T (Jerusalem^ Cremaschi A, Geroni P (Romano di Lombardia), Gion M, Saracchini S (Venice), Molina R (Barcelona), Namer N (Nice), Stieber P (Munich), Sturgeon C, Leonard RCF (Edinburgh), Einarsson R (Stockholm). Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes. The Breast. 5:82-88,1996.
15. Van Dalen A, Barak V, Cremaschi A, et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 13:10-15,1998.
16. Barak V, Livni N, Peretz T, Libson Y, Manny J, Durst AL and Roisman l. The role of CA 15-3 expression in serum and tissue of breast cancer patients. J Tumor Marker Oncology. 10(3):39-45, 1995.
17. Roisman I, Livni N, Israeli A, Lifshitz I, Libson Y, Manny J, Durst AL, Barak V. The significance of the ÇA I5-3 tumor marker as an additional tool for detection of breast cancer. J Tumor Markers Oncology. 9(3): 1924,1994.
18. Nisman B, Lafair J, Heshing J, Liass O, Peretz T, Barak V. Evaluation of TPS, Cyfra 21-1 and CEA in nonsmall cell lung cancer: does the combined use of cytokeratin markers give any additional information? Cancer 82:1850-1859, 1998.
19. Perez EA. Paclitaxel in Breast Cancer. The Oncologist 3: 373-389, 1998.
20. Robertson JFR, Pearson D, Price MR, Selby C, Blarney RW, Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 64:757-763,1991.
21. Hayes D.F. Tumor markers for breast cancer. Ann One 4:807-819, 1993.
22. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 11291135, 1995.
23. Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, Van Dalen A. Tumour Markers in Breast Cancer EGTM Recommendations. Anticancer Research 19: 2785-2820, 1999.